VivoSim Labs Inc (VIVS) Stock Analysis
Verdict: AVOID
A 7-figure pharma deal sparks a 142.9% rally, but $10.8M annual cash burn vs $5.02M cash poses severe dilution risk.
Investment score: 31/100
Analysis as of
Is VivoSim Labs Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assigns an AVOID recommendation with an investment score of 31/100 due to severe cash burn and negative equity despite recent positive contract momentum.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
VivoSim Labs Inc opportunities and risks
What speaks for VIVS
- Seven-Figure Global Pharma Testing Agreement
What speaks against VIVS
- Critical Cash Runway Deficit & Impending Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VIVS | n/a | 35.8x | 0.3x | -162.2% | -7605.9% | -212.7% |
| ERNA | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -389.8% |
| DRMA | n/a | 35.4x | 0.2x | 54.1% | -12811.5% | -344.8% |
| ORGS | n/a | 0.4x | n/a | -1080.2% | -10445.5% | -8639.7% |
| ONCO | n/a | 2.5x | 0.0x | 73.8% | -7423.9% | -781.3% |
| PMCB | n/a | 0.0x | 2.8x | 0.0% | 0.0% | -152.9% |
| Peer median | n/a | 0.4x | 0.1x | 0.0% | -7423.9% | -389.8% |
Frequently asked questions about VivoSim Labs Inc (VIVS)
Is VIVS stock a good investment?
The TradeMates model rates VivoSim Labs Inc as AVOID with an investment score of 31/100. The TradeMates model assigns an AVOID recommendation with an investment score of 31/100 due to severe cash burn and negative equity despite recent positive contract momentum. This is algorithmic model output, not personal investment advice.
Is VIVS stock a buy?
The TradeMates model verdict for VIVS is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.